Inmolecule NanotechXPAR:MLINA 6 Days Payable is 733.66 as of Dec. 2024, which is 27% above its 10-year median of 578.84. GuruFocus rates XPAR:MLINA with a GF Score™ of 6/100. The stock has 2 warning signs investors should review. Among 705 Biotechnology companies, Inmolecule Nanotech ranks better than 83.26% on this metric.
The historical rank and industry rank for Inmolecule Nanotech's Days Payable or its related term are showing as below:
XPAR:MLINA'
s Days Payable Range Over the Past 10 Years
Min: 424.02 Med: 578.84 Max: 733.66
Current: 733.66
During the past 2 years, Inmolecule Nanotech's highest Days Payable was 733.66. The lowest was 424.02. And the median was 578.84.
XPAR:MLINA's Days Payable is ranked better than 83.26% of 705
companies
in the Biotechnology industry
Industry Median: 113.36
vs XPAR:MLINA: 733.66
Inmolecule Nanotech's Days Payable
increased
from . 20 (0.00) to Dec. 2024 (733.66).
It may suggest that Inmolecule Nanotechdelayed paying its suppliers.
Inmolecule Nanotech Days Payable Related Terms
Inmolecule Nanotech Days Payable Historical Data
* Premium members only.
The historical data trend for Inmolecule Nanotech's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inmolecule Nanotech Days Payable Chart
Inmolecule Nanotech Annual Data
Trend
Dec23
Dec24
Days Payable
424.02
733.66
Inmolecule Nanotech Semi-Annual Data
Dec23
Dec24
Days Payable
424.02
733.66
XPAR:MLINA vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Inmolecule Nanotech's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inmolecule Nanotech Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Inmolecule Nanotech's Days Payable distribution charts can be found below:
* The bar in red indicates where Inmolecule Nanotech's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Inmolecule Nanotech's Days Payable for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inmolecule Nanotech (XPAR:MLINA) has a Days Payable of 733.66 as of Dec. 2024. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Inmolecule Nanotech and its competitors. This is 27% above median its historical median of 578.84. Over the past decade, Inmolecule Nanotech's Days Payable has ranged from 424.02 to 733.66. According to the industry distribution chart, Inmolecule Nanotech ranks #118 out of 705 companies in the Biotechnology industry, placing it in the top 16.7%.
Is Inmolecule Nanotech's Days Payable too high?
Inmolecule Nanotech's current Days Payable of 733.66 is 27% above median its 10-year median of 578.84. Over the past 10 years, this metric has ranged from a low of 424.02 to a high of 733.66. The Biotechnology industry median Days Payable is 113.36. Inmolecule Nanotech's value of 733.66 is 547.2% above this industry median. Based on the distribution chart, Inmolecule Nanotech ranks #118 out of 705 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Inmolecule Nanotech has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Inmolecule Nanotech's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Inmolecule Nanotech ranks #118 out of 705 companies for Days Payable. This places Inmolecule Nanotech in the top 17% of its industry — outperforming the majority of peers. The industry median Days Payable is 113.36. Inmolecule Nanotech's value of 733.66 is 547.2% above this benchmark. Historically, Inmolecule Nanotech's own Days Payable has ranged from 424.02 to 733.66 over the past decade. While the company's 10-year median is 578.84 vs. the industry median of 113.36, Inmolecule Nanotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.36, based on 705 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Inmolecule Nanotech's current Days Payable of 733.66 is 547.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Inmolecule Nanotech and its competitors. For the Biotechnology industry, the median Days Payable is 113.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Inmolecule Nanotech's current Days Payable is 733.66, which is 27% above median its own 10-year median of 578.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inmolecule Nanotech stock overvalued right now?
Inmolecule Nanotech (XPAR:MLINA) has a current Days Payable of 733.66. The current Days Payable is 733.66, which is 27% above median its 10-year median of 578.84 and 547.2% above the Biotechnology industry median of 113.36. Inmolecule Nanotech's overall GF Score™ is 6/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Inmolecule Nanotech (XPAR:MLINA), the current Days Payable is 733.66 as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:MLINA has been successfully added to your 